logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10093620 B1

PDFFull Text
Date of Patent:
Oct. 09, 2018

Filed:

Sep. 11, 2015

Compositions and methods for treatment of prostate carcinoma

Applicant:

Pellficure Pharmaceuticals, Inc., San Diego, CA (US);

Inventors:

Per Borgström, La Jolla, CA (US);

Adrian Chrastina, Chula Vista, CA (US);

Veronique Therese Baron, Carlsbad, CA (US);

Parisa Abedinpour, San Diego, CA (US);

Assignee:

PELLFICURE PHARMACEUTICALS, INC., La Jolla, CA (US);

Attorney:

Knobbe Martens Olson & Bear LLP

Primary Examiner:

Pancham Bashi

Int. Cl.
CPC ...
C07C 323/61 (2006.01); C07C 50/32 (2006.01); A61K 31/122 (2006.01); C07C 233/25 (2006.01); A61K 31/167 (2006.01); C07C 217/60 (2006.01); A61K 31/137 (2006.01); C07C 205/36 (2006.01); C07C 69/92 (2006.01); A61K 31/235 (2006.01); C07C 271/46 (2006.01); A61K 31/325 (2006.01); C07C 225/30 (2006.01); A61K 31/135 (2006.01); A61K 31/136 (2006.01); C07C 311/51 (2006.01); A61K 31/18 (2006.01); C07C 311/16 (2006.01); C07C 233/23 (2006.01); A61K 31/165 (2006.01); C07C 69/63 (2006.01); A61K 31/222 (2006.01); A61K 31/573 (2006.01); A61K 31/58 (2006.01); A61K 31/56 (2006.01); A61K 31/4166 (2006.01); A61K 31/277 (2006.01); A61K 31/05 (2006.01); A61K 31/661 (2006.01); A61K 31/496 (2006.01); A61K 31/45 (2006.01); A61K 31/4164 (2006.01);
U.S. Cl.
CPC ...
C07C 323/61 (2013.01); A61K 31/05 (2013.01); A61K 31/122 (2013.01); A61K 31/135 (2013.01); A61K 31/136 (2013.01); A61K 31/137 (2013.01); A61K 31/165 (2013.01); A61K 31/167 (2013.01); A61K 31/18 (2013.01); A61K 31/222 (2013.01); A61K 31/235 (2013.01); A61K 31/277 (2013.01); A61K 31/325 (2013.01); A61K 31/4164 (2013.01); A61K 31/4166 (2013.01); A61K 31/45 (2013.01); A61K 31/496 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 31/661 (2013.01); C07C 50/32 (2013.01); C07C 69/63 (2013.01); C07C 69/92 (2013.01); C07C 205/36 (2013.01); C07C 217/60 (2013.01); C07C 225/30 (2013.01); C07C 233/23 (2013.01); C07C 233/25 (2013.01); C07C 271/46 (2013.01); C07C 311/16 (2013.01); C07C 311/51 (2013.01);
Abstract

Disclosed herein are 1,4-naphthoquinone analogs, pharmaceutical compositions that include one or more of such 1,4-naphthoquinone analogs, and methods of treating and/or ameliorating diseases and/or conditions associated with a cancer, such as prostate cancer with such 1,4-naphthoquinone analogs. Also included are combination therapies wherein a 1,4-naphthoquinone analog disclosed herein, and a hormone therapy agent are provided to a subject suffering from a condition such as cancer.

Find Patent Forward Citations

Loading…